Cannabis Stocks Surge: Trump Marijuana Reclassification Report

Trump Governance Poised to Loosen Federal Marijuana Restrictions, Sending Cannabis Stocks Soaring

A potential reclassification of marijuana by the federal government is fueling a surge in cannabis stock prices, as former President Trump reportedly plans to direct agencies to ease restrictions on the plant. The move comes as the Biden administration previously initiated a review of marijuana’s classification, setting the stage for notable industry changes.

The Washington Post reported Thursday that Trump intends to instruct federal agencies to reclassify marijuana as a Schedule III drug. This shift would substantially reduce oversight, aligning it with commonly prescribed painkillers and other medications. The news immediately impacted the market, with shares of several cannabis companies experiencing substantial gains Friday morning.

Did you know? – The current Schedule I classification of marijuana, alongside heroin, implies it has no accepted medical use and a high potential for abuse. Reclassification to Schedule III would acknowledge accepted medical applications.

Cannabis Stocks See Dramatic Gains

U.S.-listed cannabis companies saw a significant boost following the report.Here’s a snapshot of the market movement:

• Tilray brands Inc. (TLRY): Gained 30.24%, closing at $10.98 with a $2.55 increase.
• SNDL: Increased 21.97%, reaching $2.16 with a $0.39 rise.
• Roundhill Cannabis ETF (WEED): Jumped 40.75%, finishing at $22.90 with a $6.63 increase.
• advisorshares Pure US Cannabis ETF (MSOS): Rose 40.56%, closing at $5.29 with a $1.52 increase.

According to one analyst, the reclassification could “open the door for pharmaceutical companies to seek approval for more cannabis products, which could then be dispensed the same as other prescription drugs.”

Pro tip: – Investors should remember that cannabis stocks remain volatile. While reclassification is positive, market fluctuations are expected, and thorough research is crucial before investing.

Easing Funding Challenges and Industry Reshaping

The potential reclassification represents a major turning point for the cannabis industry, which has long struggled with access to capital due to federal restrictions. Currently, marijuana is classified as a Schedule I substance under the Controlled Substances Act, indicating a high potential for abuse and no accepted medical use. This classification has kept most banks and institutional investors away from the sector, forcing cannabis producers to rely on costly loans and choice funding sources.

“Funding remains one of the biggest challenges for cannabis producers,” the report noted. A shift to Schedule III would likely ease these constraints, potentially lowering taxes and facilitating easier access to funding.

The move is also expected to catalyze further developments within the industry. Alliance Global Partners analyst Aaron Gray suggested that this could lead to “additional states legalizing cannabis, safer banking being passed, and the ultimate uplisting of plant-touching cannabis stocks to major US exchanges.”

The Biden administration last year requested the Department of Health and

Reader question: – How might this reclassification impact the existing state-legal cannabis markets? What challenges or opportunities do you foresee for businesses already operating in those states?